UBS Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $137.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently ...
Market Inference3d
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as CMO
Before joining Neurocrine, Dr. Keswani served as the President and Chief Executive Officer of Immunobrain, a clinical-stage ...
Le Lézard4d
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences, Inc. today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an ...
Neurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ ...